David Dodd has served as the President and CEO of GeoVax Labs, Inc. since 2018. Mr. Dodd joined the GeoVax Board of Directors in March 2010 and was elected Chairman in January 2011. Since being appointed President, and CEO, Mr. Dodd has led GeoVax through a corporate recapitalization and up-listing to Nasdaq, followed by the Company acquiring the exclusive worldwide rights to two Phase 2-status products. This includes GEO-CM04S1, a next-generation vaccine for Covid-19, currently in multiple Phase 2, multi-site clinical trials, and Gedeptin®, a gene-directed cancer therapy against solid tumors, currently completing a multi-site Phase 1/2 trial, funded by the FDA Orphan Drugs Clinical Trials Program. During his career, Mr. Dodd has overseen the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5 billion in financial transactions, and over $5 billion in incremental enterprise growth. Mr. Dodd’s achievements also include successful IPO listings, re-capitalizations, and corporate developments in multiple international jurisdictions. Mr. Dodd has served in executive roles with Wyeth, now part of Pfizer, Bristol-Myers Squibb, Abbott Laboratories and Serologicals Corporation. Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University and completed the Advanced Management Program of Harvard Business School.